These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11748582)

  • 41. Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling.
    Scaltriti M; Belloni L; Caporali A; Davalli P; Remondini D; Rizzi F; Astancolle S; Corti A; Bettuzzi S
    Carcinogenesis; 2006 May; 27(5):1047-53. PubMed ID: 16314398
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A systems approach to model metastatic progression.
    Taylor BS; Varambally S; Chinnaiyan AM
    Cancer Res; 2006 Jun; 66(11):5537-9. PubMed ID: 16740685
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers.
    Arlt F; Stein U
    Int J Biochem Cell Biol; 2009 Dec; 41(12):2356-9. PubMed ID: 19666136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical utility of microarray-derived genetic signatures in predicting outcomes in prostate cancer.
    Reddy GK; Balk SP
    Clin Genitourin Cancer; 2006 Dec; 5(3):187-9. PubMed ID: 17239271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heat shock proteins in prostate cancer: from tumorigenesis to the clinic.
    Ciocca DR; Fanelli MA; Cuello-Carrion FD; Castro GN
    Int J Hyperthermia; 2010; 26(8):737-47. PubMed ID: 20858068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biomarkers in cancer micrometastasis: where are we at?
    Gerges N; Jabado N
    Bioanalysis; 2010 May; 2(5):881-99. PubMed ID: 21083219
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protein 4.1B suppresses prostate cancer progression and metastasis.
    Wong SY; Haack H; Kissil JL; Barry M; Bronson RT; Shen SS; Whittaker CA; Crowley D; Hynes RO
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12784-9. PubMed ID: 17640904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thinking outside the box: using metastasis suppressors as molecular tools.
    Thiolloy S; Rinker-Schaeffer CW
    Semin Cancer Biol; 2011 Apr; 21(2):89-98. PubMed ID: 21147228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Requirements for an idealized animal model of prostatic cancer.
    Coffey DS; Isaacs JT
    Prog Clin Biol Res; 1980; 37():379-91. PubMed ID: 7384094
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The metastatic process: basic research and clinical implications.
    Chambers AF
    Oncol Res; 1999; 11(4):161-8. PubMed ID: 10566614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential proteomic alterations between localised and metastatic prostate cancer.
    Taylor BS; Varambally S; Chinnaiyan AM
    Br J Cancer; 2006 Aug; 95(4):425-30. PubMed ID: 16880794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Defining the biologic role of genes that regulate prostate cancer metastasis.
    Rinker-Schaeffer CW; Welch DR; Sokoloff M
    Curr Opin Urol; 2000 Sep; 10(5):397-401. PubMed ID: 11005442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.
    Varambally S; Yu J; Laxman B; Rhodes DR; Mehra R; Tomlins SA; Shah RB; Chandran U; Monzon FA; Becich MJ; Wei JT; Pienta KJ; Ghosh D; Rubin MA; Chinnaiyan AM
    Cancer Cell; 2005 Nov; 8(5):393-406. PubMed ID: 16286247
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metastasis progression is a clonally selective process on whole-body level.
    Li Z; Fan QY; Ma BA; Zhou Y; Zhang MH; Zhang Y
    Med Hypotheses; 2009 Nov; 73(5):797-8. PubMed ID: 19473776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cellular determinants and microenvironmental regulation of prostate cancer metastasis.
    Rycaj K; Li H; Zhou J; Chen X; Tang DG
    Semin Cancer Biol; 2017 Jun; 44():83-97. PubMed ID: 28408152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of new prostate cancer progression markers by differential hybridization analysis.
    Schalken JA; Debruyne FM
    Eur Urol; 1992; 21 Suppl 1():60-5. PubMed ID: 1425840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular biology of prostate cancer.
    Schulz WA; Burchardt M; Cronauer MV
    Mol Hum Reprod; 2003 Aug; 9(8):437-48. PubMed ID: 12837920
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Markers of the metastatic phenotype in prostate cancer.
    Foster CS; McLoughlin J; Bashir I; Abel PD
    Hum Pathol; 1992 Apr; 23(4):381-94. PubMed ID: 1563738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of tumor metastasis suppressors in cancers of breast and prostate.
    Furuta E; Bandyopadhyay S; Iiizumi M; Mohinta S; Zhan R; Watabe K
    Front Biosci; 2006 Sep; 11():2845-60. PubMed ID: 16720356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proteomics in investigation of cancer metastasis: functional and clinical consequences and methodological challenges.
    Maryáš J; Faktor J; Dvořáková M; Struhárová I; Grell P; Bouchal P
    Proteomics; 2014 Mar; 14(4-5):426-40. PubMed ID: 24272997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.